Cefpodoxime: Difference between revisions
m (Protected "Cefpodoxime": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
| Line 24: | Line 24: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
'''Cefpodoxime''' (marketed as the [[prodrug]] '''cefpodoxime proxetil''' by [[Pharmacia & Upjohn]] under the trade name '''Vantin®''') is an oral third generation [[cephalosporin]] [[antibiotic]]. It is active against most [[Gram positive]] and [[Gram negative]] [[bacteria]]. Notable exceptions include ''[[Pseudomonas aeruginosa]]'', ''[[Enterococcus]]'', and ''[[Bacteroides|Bacteroides fragilis]]''. It is commonly used to treat acute [[otitis media]], [[pharyngitis]], and [[sinusitis]]. It also finds use as oral continuation therapy when [[intravenous]] cephalosporins (such as [[ceftriaxone]]) are no longer necessary for continued treatment. [[Pfizer]], the parent company of [[Pharmacia & Upjohn]], markets '''Cefpodoxime proxetil''' under the trade name '''Simplicef®''' for veterinary use. The dose range in dogs is 5-10 mg/kg body weight, administered orally, once a day. Outside the US, Cefpodoxime proxetil is marketed as '''Banan®.''' | '''Cefpodoxime''' (marketed as the [[prodrug]] '''cefpodoxime proxetil''' by [[Pharmacia & Upjohn]] under the trade name '''Vantin®''') is an oral third generation [[cephalosporin]] [[antibiotic]]. It is active against most [[Gram positive]] and [[Gram negative]] [[bacteria]]. Notable exceptions include ''[[Pseudomonas aeruginosa]]'', ''[[Enterococcus]]'', and ''[[Bacteroides|Bacteroides fragilis]]''. It is commonly used to treat acute [[otitis media]], [[pharyngitis]], and [[sinusitis]]. It also finds use as oral continuation therapy when [[intravenous]] cephalosporins (such as [[ceftriaxone]]) are no longer necessary for continued treatment. [[Pfizer]], the parent company of [[Pharmacia & Upjohn]], markets '''Cefpodoxime proxetil''' under the trade name '''Simplicef®''' for veterinary use. The dose range in dogs is 5-10 mg/kg body weight, administered orally, once a day. Outside the US, Cefpodoxime proxetil is marketed as '''Banan®.''' | ||
| Line 41: | Line 41: | ||
[[th:เซฟโปดอกซิม]] | [[th:เซฟโปดอกซิม]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 23:36, 8 August 2012
| File:Cefpodoxime.svg | |
| Clinical data | |
|---|---|
| Pregnancy category | |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 50% |
| Protein binding | 21% to 29% |
| Metabolism | Negligible. Cefpodoxime proxetil is metabolized to cefpodoxime by the liver |
| Elimination half-life | 2 hours |
| Excretion | Renal, unchanged |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C15H17N5O6S2 |
| Molar mass | 427.458 g/mol |
|
WikiDoc Resources for Cefpodoxime |
|
Articles |
|---|
|
Most recent articles on Cefpodoxime Most cited articles on Cefpodoxime |
|
Media |
|
Powerpoint slides on Cefpodoxime |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Cefpodoxime at Clinical Trials.gov Clinical Trials on Cefpodoxime at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Cefpodoxime
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Cefpodoxime Discussion groups on Cefpodoxime Patient Handouts on Cefpodoxime Directions to Hospitals Treating Cefpodoxime Risk calculators and risk factors for Cefpodoxime
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Cefpodoxime |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Cefpodoxime (marketed as the prodrug cefpodoxime proxetil by Pharmacia & Upjohn under the trade name Vantin®) is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative bacteria. Notable exceptions include Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. It also finds use as oral continuation therapy when intravenous cephalosporins (such as ceftriaxone) are no longer necessary for continued treatment. Pfizer, the parent company of Pharmacia & Upjohn, markets Cefpodoxime proxetil under the trade name Simplicef® for veterinary use. The dose range in dogs is 5-10 mg/kg body weight, administered orally, once a day. Outside the US, Cefpodoxime proxetil is marketed as Banan®.
External links
- Template:PubChem - cefpodoxime proxetil
- Vantin Tablets and Oral Suspension Full U.S. Prescribing Information (from manufacturer's website)
- Simplicef (from manufacturer's website)
- Pages with script errors
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Cephalosporin antibiotics